NBY: Summary for NOVABAY PHARMACEUTCL - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 12:10am EST - Canadian Markets open in 9 hours and 20 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

NovaBay Pharmaceuticals, Inc. (NBY)

On Feb 9: 2.24 USD

0.01 (0.44%)

MORE ON NBY

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

NOVABAY PHARMACEUTCL (AMEX:NBY) Delayed quote data

Last Trade:	2.24 USD
Trade Time:	Feb 9
Change:	0.01 (0.44%)
Prev Close:	2.25
Open:	2.25
Bid:	N/A
Ask:	N/A
1y Target Est:	5.40

Day's Range:	2.20 - 2.25
52wk Range:	1.12 - 3.24
Volume:	15,550
Avg Vol (3m):	26,676.2
Market Cap:	52.09M
P/E (ttm):	N/A
EPS (ttm):	-0.10
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Free Annual Reports

Add NBY to Portfolio

Download Data

HEADLINES

•	NovaBay Pharmaceuticals to Present at the 2010 BIO CEO & Investor Conference
	Marketwire (Thu, Feb 4)

•	NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles o
	EDGAR Online (Tue, Jan 26)

•	NovaBay Pharmaceuticals Earns $3.75 Million in Milestone Payments From Galderma, S.A.
	Marketwire (Mon, Jan 11)

•	NovaBay Pharmaceuticals to Present at the Annual OneMedPlace Finance Forum
	Marketwire (Thu, Jan 7)

•	NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
	EDGAR Online (Wed, Dec 23)

•	NovaBay Pharmaceuticals to Receive Increase in Funding and Support From Alcon
	Marketwire (Thu, Dec 17)

•	NOVABAY PHARMACEUTICALS, INC. Financials
	EDGAR Online Financials (Tue, Nov 17)

•	New Star Analyst Rankings for NOVABAY PHARMACEUTCL
	StarMine (Mon, Nov 16)

•	NovaBay Pharmaceuticals Reports Third Quarter Financials and Provides Update on Pipeline of Anti-Infective Compounds
	Marketwire (Fri, Nov 13)

•	NOVABAY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Thu, Nov 12)

More Headlines for NBY...

ANALYST

EPS Est (next year) (Dec-09) :	-0.05
EPS Est (in 2 years) (Dec-10) :	-0.06
Avg Rec (current)*:	2.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

NovaBay Pharmaceuticals, Inc., a mid-stage biopharmaceutical company, focuses on developing product candidates for the treatment or prevention of a range of infections in hospital and non-hospital environments.

Full Company Profile

Add to Portfolio

Email to a Friend

•